123 related articles for article (PubMed ID: 20646614)
21. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
23. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
24. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
26. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
28. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
29. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
30. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
[No Abstract] [Full Text] [Related]
31. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
[TBL] [Abstract][Full Text] [Related]
32. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
33. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
[TBL] [Abstract][Full Text] [Related]
34. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
[TBL] [Abstract][Full Text] [Related]
35. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
[TBL] [Abstract][Full Text] [Related]
36. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.
Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC
Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244
[TBL] [Abstract][Full Text] [Related]
37. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
39. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
40. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
